Common Contracts

IND SPONSOR: InCHOIR CLINICAL TRIAL AGREEMENT BETWEEN THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (“NHLBI”) AND Mesoblast, Inc. Protocol # CTSNLVAD02

Clinical Trial Agreement • November 2nd, 2015 • Mesoblast LTD • Biological products, (no disgnostic substances) • District of Columbia

• Contract Type
  Clinical Trial Agreement
• Filed
  November 2nd, 2015
• Company
  Mesoblast LTD
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  District of Columbia

This Clinical Trial Agreement (the “Agreement”), effective as of July 28th, 2014 (the “Effective Date”) is made by and between the National Heart, Lung, and Blood Institute (“NHLBI”), an institute of the National Institutes of Health (“NIH”), which is part of the United States Government Department of Health and Human Services (HHS), and Mesoblast, Inc. (“Company”), located at 505 Fifth Ave., 3rd Floor, New York, NY 10017 (individually referred to as the “Party” and collectively referred to as the “Parties”) for a Clinical Trial designated as Protocol # CTSNLVAD02 entitled “Safety and Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients.”

IND SPONSOR: InCHOIR CLINICAL TRIAL AGREEMENT BETWEEN THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (“NHLBI”) AND Mesoblast, Inc. Protocol # CTSNLVAD02

Clinical Trial Agreement • December 10th, 2014 • Mesoblast LTD • Biological products, (no disgnostic substances) • District of Columbia

• Contract Type
  Clinical Trial Agreement
• Filed
  December 10th, 2014
• Company
  Mesoblast LTD
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  District of Columbia

This Clinical Trial Agreement (the “Agreement”), effective as of July , 2014 (the “Effective Date”) is made by and between the National Heart, Lung, and Blood Institute (“NHLBI”), an institute of the National Institutes of Health (“NIH”), which is part of the United States Government Department of Health and Human Services (HHS), and Mesoblast, Inc. (“Company”), located at 505 Fifth Ave., 3rd Floor, New York, NY 10017 (individually referred to as the “Party” and collectively referred to as the “Parties”) for a Clinical Trial designated as Protocol # CTSNLVAD02 entitled “Safety and Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients.”